Cite
HARVARD Citation
Cooper, T. et al. (2017). A phase 1 study of the CXCR4 antagonist plerixafor in combination with high‐dose cytarabine and etoposide in children with relapsed or refractory acute leukemias or myelodysplastic syndrome: A Pediatric Oncology Experimental Therapeutics Investigators' Consortium study (POE 10‐03). Pediatric blood & cancer. 64 (8), p. n/a. [Online].